

## Balixafortide TFA (1051366-32-5 free base)

## Chemical Properties

CAS No. :

Formula: C<sub>82</sub>H<sub>113</sub>N<sub>22</sub>F<sub>30</sub>O<sub>23</sub>S<sub>2</sub>

Molecular Weight: 1896.05

Keep away from moisture

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.

## Biological Description

Description	Balixafortide TFA (POL6326 TFA) is a selective, well-tolerated peptidic CXCR4 antagonist (IC <sub>50</sub> < 10 nM). It shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux (IC <sub>50</sub> s < 10 nM).
Targets(IC <sub>50</sub> )	CXCR
In vitro	Balixafortide efficiently blocks SDF-1 dependent chemotaxis of MDA MB 231 breast cancer cells (IC <sub>50</sub> < 20 nM), Namalwa and Jurkat cells (IC <sub>50</sub> < 10 nM). Balixafortide potently inhibits pERK / pAKT signaling in the lymphoma lines Jurkat (IC <sub>50</sub> < 400 nM) and Namalwa (IC <sub>50</sub> < 200 nM) [1].
In vivo	Balixafortide is optimized for favorable mouse absorption, distribution, metabolism, and excretion (ADME) properties with balanced plasma protein binding, microsomal stability, and greater plasma.

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.5274 mL	2.6371 mL	5.2741 mL
5 mM	0.1055 mL	0.5274 mL	1.0548 mL
10 mM	0.0527 mL	0.2637 mL	0.5274 mL
50 mM	0.0105 mL	0.0527 mL	0.1055 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Zimmermann J, et al. Anti-tumor cell activity and in vitro profile of the next generation CXCR4 antagonist Balixafortide. Ann Oncol. 2018 Oct;29 Suppl 8:viii103.

Karpova D, et al. Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial. J Transl Med. 2017 Jan 3;15(1):2.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481